FEASIBILITY OF MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF OMALIZUMAB (OMA) VS. MEPOLIZUMAB (MEPO) IN MODERATE-TO-SEVERE ASTHMA

Author(s)

Ayyagari R1, Álvares L2, Mu F1, Hacking V3, Martinez R2, Signorovitch JE1
1Analysis Group, Inc., Boston, MA, USA, 2Novartis Pharma AG, Basel, Switzerland, 3Novartis Pharmaceuticals UK Ltd, Surrey, UK

OBJECTIVES: The relative efficacy of OMA to MEPO for asthma patients has not been studied in randomized clinical trials (RCTs). Naïve indirect comparisons (ICs) are invalid due to differences between trials. The feasibility of an IC using MAIC is unknown. This study aims to assess feasibility of a MAIC of efficacy of OMA vs. MEPO. METHODS:

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PRS3

Topic

Clinical Outcomes

Topic Subcategory

Comparative Effectiveness or Efficacy

Disease

Respiratory-Related Disorders

Explore Related HEOR by Topic

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×